Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis-Reference-Cited by-同舟云学术

Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis

Published:2023-11-24 Issue:1 Volume:41 Page:413-430
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Cheng Wendy Y.,Fishman Jesse,Yenikomshian Mihran,Mahendran Malena,Kunzweiler Colin,Vu Jensen Duy,Duh Mei Sheng

Funder

Apellis Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02725-5.pdf

Reference43 articles.

1. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https://doi.org/10.1038/nrdp.2017.28.

2. Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology. J Manag Care Spec Pharm. 2020;26(12-b Suppl):S3–8. https://doi.org/10.18553/jmcp.2020.26.12-b.s3.

3. Jalbert JJ, Chaudhari U, Zhang H, et al. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement_1):3407. https://doi.org/10.1182/blood-2019-125867.

4. Hill A, Platts PJ, Smith A, et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 2006;108(11):985. https://doi.org/10.1182/blood.V108.11.985.985.

5. Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505–14. https://doi.org/10.1007/s00277-020-04052-z.